Skip to main content

Dermata Therapeutics, Inc.

DRMA
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
SEC CIK
0001853816

No open-market purchases or sales by Dermata Therapeutics, Inc. insiders were filed in the last 90 days; 13 institutions reported holding it in 13F filings for Q2 2026, worth $158.0K in total; no superinvestor holds it.

Q4 2022 vs. Q3 2022

How the institutions holding Dermata Therapeutics, Inc. changed between Q3 2022 and Q4 2022.

All holders in Q4 2022All holders in Q3 2022

13F holders of DRMA: Q3 2022 compared with Q4 2022
MeasureQ3 2022Q4 2022Change
Holders911+2
Shares197.2K292.8K+95.5K (+48.4%)
Value$101.0K$118.8K+$17.8K (+17.6%)

New holders (5)

Institutions that held Dermata Therapeutics, Inc. at the end of Q4 2022 but not at the end of Q3 2022.

Institutions new to DRMA in Q4 2022
InstitutionSharesValue% of portfolio
Raymond James Financial Services Advisors, Inc.141,763$58.0K0.00%
Financial Advisory Service, Inc.12,698$5.19K0.00%
Two Sigma Securities, LLC12,434$5.09K0.00%
HC Advisors, LLC10,000$4.09K0.00%
Morgan Stanley562$2300.00%

Sold out (3)

Institutions that held Dermata Therapeutics, Inc. at the end of Q3 2022 and filed for Q4 2022 without it.

Institutions that sold out of DRMA in Q4 2022
InstitutionShares, Q3 2022Value, Q3 2022
Virtu Financial LLC70,808$37.0K
Jane Street Group, LLC23,565$12.0K
FMR LLC10,000$5.00K